HUE042261T2 - Gén kikapcsolásra alkalmas konzervált HBV és HCV szekvenciák - Google Patents
Gén kikapcsolásra alkalmas konzervált HBV és HCV szekvenciákInfo
- Publication number
- HUE042261T2 HUE042261T2 HUE10180048A HUE10180048A HUE042261T2 HU E042261 T2 HUE042261 T2 HU E042261T2 HU E10180048 A HUE10180048 A HU E10180048A HU E10180048 A HUE10180048 A HU E10180048A HU E042261 T2 HUE042261 T2 HU E042261T2
- Authority
- HU
- Hungary
- Prior art keywords
- gene silencing
- sequences useful
- hcv sequences
- conserved hbv
- hbv
- Prior art date
Links
- 230000030279 gene silencing Effects 0.000 title 1
- 238000012226 gene silencing method Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47807603P | 2003-06-12 | 2003-06-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE042261T2 true HUE042261T2 (hu) | 2019-06-28 |
Family
ID=34135047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE10180048A HUE042261T2 (hu) | 2003-06-12 | 2004-06-10 | Gén kikapcsolásra alkalmas konzervált HBV és HCV szekvenciák |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8350021B2 (enExample) |
| EP (4) | EP2284268A3 (enExample) |
| JP (2) | JP4980716B2 (enExample) |
| CN (1) | CN1836042A (enExample) |
| AU (1) | AU2004263832B2 (enExample) |
| BR (1) | BRPI0411219A (enExample) |
| CA (2) | CA2528510C (enExample) |
| DK (1) | DK2270162T3 (enExample) |
| HU (1) | HUE042261T2 (enExample) |
| IL (1) | IL172268A0 (enExample) |
| SG (1) | SG173218A1 (enExample) |
| SI (1) | SI2270162T1 (enExample) |
| WO (1) | WO2005014806A2 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2284268A3 (en) | 2003-06-12 | 2012-05-30 | Alnylam Pharmaceuticals Inc. | Conserved HBV and HCV sequences useful for gene silencing |
| US8575327B2 (en) | 2003-06-12 | 2013-11-05 | Alnylam Pharmaceuticals, Inc. | Conserved HBV and HCV sequences useful for gene silencing |
| US20070265220A1 (en) | 2004-03-15 | 2007-11-15 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| US8084599B2 (en) | 2004-03-15 | 2011-12-27 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| US7985581B2 (en) | 2004-08-23 | 2011-07-26 | Alnylam Pharmaceuticals, Inc. | Multiple RNA polymerase III promoter expression constructs |
| EP2772541A3 (en) * | 2004-09-24 | 2014-09-24 | Alnylam Pharmaceuticals Inc. | Targeting opposite strand replication intermediates of hepatitis C virus by RNAi |
| DE602005027747D1 (de) * | 2004-12-22 | 2011-06-09 | Alnylam Pharmaceuticals Inc | Zum gen-silencing geeignete konservierte hbv- und hcv-sequenzen |
| WO2011103394A2 (en) * | 2010-02-19 | 2011-08-25 | Agave Pharma Inc. | Methods for gene inhibition |
| CA2791974A1 (en) | 2010-03-01 | 2011-09-09 | The Children's Hospital Of Philadelphia | Nucleic acids for targeting multiple regions of the hcv genome |
| EP2606134B1 (en) | 2010-08-17 | 2019-04-10 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US8642752B2 (en) * | 2011-04-21 | 2014-02-04 | Isis Pharmaceuticals, Inc. | Modulation of Hepatitis B virus (HBV) expression |
| EP2890403A4 (en) | 2012-08-30 | 2016-03-09 | Replicor Inc | METHOD FOR THE TREATMENT OF HEPATITIS B AND HEPATITIS D INFECTIONS |
| CA2916694C (en) | 2013-06-28 | 2023-01-17 | Baylor Research Institute | Dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis |
| RU2016128077A (ru) | 2013-12-12 | 2018-12-06 | Те Брод Инститьют Инк. | Доставка, применение и применения в терапии систем и композиций crispr-cas для лечения обусловленных hbv и вирусных заболеваний и нарушений |
| SG11201703638XA (en) | 2014-11-10 | 2017-06-29 | Alnylam Pharmaceuticals Inc | Hepatitis b virus (hbv) irna compositions and methods of use thereof |
| CA2984512A1 (en) * | 2015-05-06 | 2016-11-10 | Benitec Biopharma Limited | Reagents for treatment of hepatitis b virus (hbv) infection and use thereof |
| US20170137821A1 (en) | 2015-07-17 | 2017-05-18 | Arcturus Therapeutics, Inc. | Molecules and agents for treating hepatitis b virus |
| CA2996722A1 (en) | 2015-07-17 | 2017-01-26 | Arcturus Therapeutics, Inc. | Compositions and agents against hepatitis b virus and uses thereof |
| TWI794662B (zh) | 2016-03-14 | 2023-03-01 | 瑞士商赫孚孟拉羅股份公司 | 用於降低pd-l1表現之寡核苷酸 |
| AU2017285350A1 (en) | 2016-06-17 | 2018-12-20 | F. Hoffmann-La Roche Ag | Nucleic acid molecules for reduction of PAPD5 or PAPD7 mRNA for treating hepatitis B infection |
| AU2017368050A1 (en) | 2016-11-29 | 2019-06-20 | Puretech Lyt, Inc. | Exosomes for delivery of therapeutic agents |
| US11324820B2 (en) | 2017-04-18 | 2022-05-10 | Alnylam Pharmaceuticals, Inc. | Methods for the treatment of subjects having a hepatitis b virus (HBV) infection |
| WO2019051812A1 (zh) * | 2017-09-15 | 2019-03-21 | 深圳华大智造科技有限公司 | 确定预定染色体保守区域的方法、确定样本基因组中是否存在拷贝数变异的方法、系统和计算机可读介质 |
| CN111511914B (zh) | 2017-10-16 | 2023-11-17 | 豪夫迈·罗氏有限公司 | 减少PAPD5和PAPD7 mRNA的核酸分子用于治疗乙型肝炎感染 |
| EP3775208A1 (en) | 2018-04-05 | 2021-02-17 | F. Hoffmann-La Roche AG | Use of fubp1 inhibitors for treating hepatitis b virus infection |
| WO2020007892A1 (en) | 2018-07-03 | 2020-01-09 | F. Hoffmann-La Roche Ag | Oligonucleotides for modulating tau expression |
| JP7616987B2 (ja) | 2018-07-13 | 2025-01-17 | エフ． ホフマン－ラ ロシュ アーゲー | Ｒｔｅｌ１発現の調節用のオリゴヌクレオチド |
| MA70658B1 (fr) | 2018-08-13 | 2026-04-30 | Alnylam Pharmaceuticals, Inc. | Compositions d'agent d'arndb du virus de l'hépatite b (vhb) et leurs méthodes d'utilisation |
| WO2021122735A1 (en) | 2019-12-19 | 2021-06-24 | F. Hoffmann-La Roche Ag | Use of sept9 inhibitors for treating hepatitis b virus infection |
| WO2021122921A1 (en) | 2019-12-19 | 2021-06-24 | F. Hoffmann-La Roche Ag | Use of cops3 inhibitors for treating hepatitis b virus infection |
| WO2021122869A1 (en) | 2019-12-19 | 2021-06-24 | F. Hoffmann-La Roche Ag | Use of scamp3 inhibitors for treating hepatitis b virus infection |
| EP4077671A1 (en) | 2019-12-19 | 2022-10-26 | F. Hoffmann-La Roche AG | Use of saraf inhibitors for treating hepatitis b virus infection |
| CN114829601A (zh) | 2019-12-19 | 2022-07-29 | 豪夫迈·罗氏有限公司 | Sbds抑制剂用于治疗乙型肝炎病毒感染的用途 |
| AR122731A1 (es) | 2020-06-26 | 2022-10-05 | Hoffmann La Roche | Oligonucleótidos mejorados para modular la expresión de fubp1 |
| EP4200419A2 (en) | 2020-08-21 | 2023-06-28 | F. Hoffmann-La Roche AG | Use of a1cf inhibitors for treating hepatitis b virus infection |
| TW202246500A (zh) | 2021-02-02 | 2022-12-01 | 瑞士商赫孚孟拉羅股份公司 | 用於抑制 ｒｔｅｌ１ 表現之增強型寡核苷酸 |
| WO2023111210A1 (en) | 2021-12-17 | 2023-06-22 | F. Hoffmann-La Roche Ag | Combination of oligonucleotides for modulating rtel1 and fubp1 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5643771A (en) | 1980-05-19 | 1997-07-01 | The Board Of Trustees Of The Leland Stanford Junior University | Non-reverting live bacterial vaccines |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| EP0400047B1 (en) | 1988-02-05 | 1997-04-23 | Whitehead Institute For Biomedical Research | Modified hepatocytes and uses therefor |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| JPH05507203A (ja) | 1990-06-18 | 1993-10-21 | アメリカ合衆国 | 真核性発現ベクター系 |
| US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
| US20030206887A1 (en) * | 1992-05-14 | 2003-11-06 | David Morrissey | RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA) |
| US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| JPH10503364A (ja) | 1994-05-10 | 1998-03-31 | ザ ジェネラル ホスピタル コーポレーション | Ｃ型肝炎ウイルスのアンチセンス阻害 |
| JPH07303485A (ja) * | 1994-05-13 | 1995-11-21 | Tonen Corp | Ｈｃｖアンチセンスｒｎａ、それを含む発現ベクター、及び該ｒｎａ又は発現ベクターを含むｈｃｖ関連疾患治療剤 |
| US5646262A (en) * | 1994-07-28 | 1997-07-08 | Georgetown University | Antisense oligonucleotides against hepatitis B viral replication |
| US5837533A (en) | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
| US5571026A (en) | 1994-12-09 | 1996-11-05 | Kcs Industries, Inc. | Flat mount electrode socket |
| US6057153A (en) * | 1995-01-13 | 2000-05-02 | Yale University | Stabilized external guide sequences |
| US5877159A (en) | 1995-05-03 | 1999-03-02 | University Of Maryland At Baltimore | Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same |
| US5932241A (en) | 1995-06-07 | 1999-08-03 | Valentis, Incorporated | Cationic lipid DNA complexes for gene targeting |
| US5824538A (en) | 1995-09-06 | 1998-10-20 | The United States Of America As Represented By The Secretary Of The Army | Shigella vector for delivering DNA to a mammalian cell |
| US5843770A (en) * | 1996-03-11 | 1998-12-01 | The Immune Response Corporation | Antisense constructs directed against viral post-transcriptional regulatory sequences |
| US5877162A (en) * | 1996-03-14 | 1999-03-02 | Innovir Laboratories, Inc. | Short external guide sequences |
| US6610478B1 (en) * | 1996-08-16 | 2003-08-26 | Yale University | Phenotypic conversion of cells mediated by external guide sequences |
| US5981274A (en) | 1996-09-18 | 1999-11-09 | Tyrrell; D. Lorne J. | Recombinant hepatitis virus vectors |
| US6217900B1 (en) | 1997-04-30 | 2001-04-17 | American Home Products Corporation | Vesicular complexes and methods of making and using the same |
| DE19725803C1 (de) | 1997-06-18 | 1999-02-11 | Deutsches Krebsforsch | HBV-gerichtete Antisense-Nukleinsäuren |
| US6287770B1 (en) | 1997-07-08 | 2001-09-11 | Cytocell Limited | Nucleic acid promoters |
| AU745805B2 (en) | 1997-10-28 | 2002-04-11 | Wyeth | Compositions and methods for delivery of genetic material |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| BR9908223A (pt) | 1998-03-16 | 2000-10-24 | Procter & Gamble | Método para reduzir celulite na pele de mamìferos |
| CA2370628A1 (en) | 1999-04-21 | 2000-10-26 | American Home Products Corporation | Methods and compositions for inhibiting the function of polynucleotide sequences |
| US6533250B2 (en) | 1999-10-15 | 2003-03-18 | W. Eugene Arthur | Energy dissipating system for a concrete roadway barrier |
| WO2003070918A2 (en) * | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | Rna interference by modified short interfering nucleic acid |
| ATE450621T2 (de) | 2000-03-30 | 2009-12-15 | Whitehead Biomedical Inst | Mediatoren von rns-interferenz, die rns- sequenzspezifisch sind |
| US7439016B1 (en) | 2000-06-15 | 2008-10-21 | Digene Corporation | Detection of nucleic acids by type-specific hybrid capture method |
| US6680059B2 (en) * | 2000-08-29 | 2004-01-20 | Tripep Ab | Vaccines containing ribavirin and methods of use thereof |
| US6443403B1 (en) | 2000-09-11 | 2002-09-03 | Panduit Corp. | Cable routing clamp and method of application |
| JP2002335968A (ja) * | 2001-05-16 | 2002-11-26 | Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho | 新規転写因子、その遺伝子及びその結合ｄｎａ配列 |
| ES2609014T3 (es) | 2001-07-12 | 2017-04-18 | University Of Massachusetts | Producción in vivo de ARN de interferencia pequeños que median el silenciamiento génico |
| WO2003013293A2 (en) | 2001-08-03 | 2003-02-20 | Michael Van Der Sleesen | Protective garment |
| US7103761B2 (en) | 2001-08-07 | 2006-09-05 | Hewlett-Packard Development Company, Lp. | Server system with multiple management user interfaces |
| US6673661B1 (en) | 2002-12-20 | 2004-01-06 | Taiwan Semiconductor Manufacturing Co., Ltd. | Self-aligned method for forming dual gate thin film transistor (TFT) device |
| WO2004078974A1 (ja) * | 2003-01-24 | 2004-09-16 | Tokyo Metropolitan Organization For Medical Research | Ｃ型肝炎ウイルスの働きを阻害するオリゴリボヌクレオチドまたはペプチド核酸 |
| CN1257284C (zh) | 2003-03-05 | 2006-05-24 | 北京博奥生物芯片有限责任公司 | 一种体外阻断乙肝病毒表达的方法 |
| EP2284268A3 (en) | 2003-06-12 | 2012-05-30 | Alnylam Pharmaceuticals Inc. | Conserved HBV and HCV sequences useful for gene silencing |
| US7985581B2 (en) * | 2004-08-23 | 2011-07-26 | Alnylam Pharmaceuticals, Inc. | Multiple RNA polymerase III promoter expression constructs |
| JP2015086965A (ja) | 2013-10-31 | 2015-05-07 | 株式会社エクセディ | フライホイール組立体 |
-
2004
- 2004-06-10 EP EP10180047A patent/EP2284268A3/en not_active Withdrawn
- 2004-06-10 DK DK10180048.0T patent/DK2270162T3/en active
- 2004-06-10 SG SG2007044373A patent/SG173218A1/en unknown
- 2004-06-10 BR BRPI0411219-9A patent/BRPI0411219A/pt not_active Application Discontinuation
- 2004-06-10 CA CA2528510A patent/CA2528510C/en not_active Expired - Lifetime
- 2004-06-10 EP EP10180048.0A patent/EP2270162B1/en not_active Expired - Lifetime
- 2004-06-10 US US10/560,377 patent/US8350021B2/en not_active Expired - Fee Related
- 2004-06-10 CN CNA2004800228949A patent/CN1836042A/zh active Pending
- 2004-06-10 HU HUE10180048A patent/HUE042261T2/hu unknown
- 2004-06-10 WO PCT/US2004/019229 patent/WO2005014806A2/en not_active Ceased
- 2004-06-10 JP JP2006533810A patent/JP4980716B2/ja not_active Expired - Fee Related
- 2004-06-10 EP EP04776661A patent/EP1631670B1/en not_active Expired - Lifetime
- 2004-06-10 CA CA3040025A patent/CA3040025C/en not_active Expired - Lifetime
- 2004-06-10 AU AU2004263832A patent/AU2004263832B2/en not_active Expired
- 2004-06-10 EP EP18192425.9A patent/EP3470518A1/en active Pending
- 2004-06-10 SI SI200432456T patent/SI2270162T1/sl unknown
-
2005
- 2005-11-30 IL IL172268A patent/IL172268A0/en unknown
-
2011
- 2011-07-04 JP JP2011148461A patent/JP5593279B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005014806A2 (en) | 2005-02-17 |
| EP2284268A3 (en) | 2012-05-30 |
| CA2528510C (en) | 2019-06-04 |
| US20080070854A1 (en) | 2008-03-20 |
| SI2270162T1 (sl) | 2019-03-29 |
| US8350021B2 (en) | 2013-01-08 |
| EP2270162B1 (en) | 2018-10-03 |
| IL172268A0 (en) | 2006-04-10 |
| WO2005014806A3 (en) | 2005-12-01 |
| JP5593279B2 (ja) | 2014-09-17 |
| EP2270162A3 (en) | 2012-05-30 |
| EP2284268A2 (en) | 2011-02-16 |
| CA3040025C (en) | 2023-01-10 |
| JP2007503474A (ja) | 2007-02-22 |
| SG173218A1 (en) | 2011-08-29 |
| JP2011224013A (ja) | 2011-11-10 |
| AU2004263832A1 (en) | 2005-02-17 |
| EP2270162A2 (en) | 2011-01-05 |
| CA3040025A1 (en) | 2005-02-17 |
| JP4980716B2 (ja) | 2012-07-18 |
| EP3470518A1 (en) | 2019-04-17 |
| EP1631670A2 (en) | 2006-03-08 |
| CN1836042A (zh) | 2006-09-20 |
| BRPI0411219A (pt) | 2006-07-18 |
| CA2528510A1 (en) | 2005-02-17 |
| EP1631670B1 (en) | 2012-08-08 |
| DK2270162T3 (en) | 2019-01-21 |
| AU2004263832B2 (en) | 2010-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL172268A0 (en) | Conserved hbv and hcv sequences useful for gene silencing | |
| AU2003265255A8 (en) | Inhibitors of hcv ns5b polymerase | |
| IL171800A (en) | Ns5b hcv inhibitors and methods based on these inhibitors | |
| EP1684745A4 (en) | INHIBITORS OF HEPATITIS C VIRUS | |
| GB2407091B (en) | Allele-specific siRNA-mediated gene silencing | |
| AU2003256334A1 (en) | Inhibitors of hcv ns5b polymerase | |
| EP1505963A4 (en) | HEPATITIS C VIRUS INHIBITORS | |
| AU2001288257A1 (en) | Improved methods of gene silencing using inverted repeat sequences | |
| AU2003224836A8 (en) | Dual-labeled nucleotides | |
| IL177503A0 (en) | Inhibitors of hepatitis c virus ns3 protease | |
| IL180755A0 (en) | Monocot ahass sequences and methods of use | |
| IL182339A0 (en) | Hcv ns3-ns4a protease inhibition | |
| AU2003258452A8 (en) | Rna interference based methods and compositions for inhibiting hbv gene expression | |
| AU2001253206A1 (en) | Ns5b hcv polymerase inhibitors | |
| PL378194A1 (pl) | Inhibitory polimerazy wirusowej | |
| SI3363809T1 (sl) | Modificirani nukleotidi za polinukleotidno sekvenciranje | |
| PL376967A1 (pl) | Szczepionka przeciw HCV | |
| AU2003256919A8 (en) | Virus induced gene silencing in plants | |
| GB0218813D0 (en) | DNA sequences from an endosymbiont and their uses | |
| SG112111A1 (en) | Chamber cleaning or etching gas regeneration and recycle method | |
| AU2012202085B2 (en) | Conserved HBV and HCV sequences useful for gene silencing | |
| AU2013257445A1 (en) | Conserved HBV and HCV sequences useful for gene silencing | |
| ZA200509528B (en) | Virtual representations of nucleotide sequences | |
| SG120968A1 (en) | Method and system for unbiased genome amplification | |
| GB0213651D0 (en) | Nucleotide sequences and uses thereof |